JPH11512736A5 - - Google Patents

Info

Publication number: JPH11512736A5
Authority: JP; Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

JP1997514119A

Other languages

English (en)

Japanese (ja)

Other versions

JPH11512736A (ja

JP4108750B2 (ja

Filing date

1996-09-18

Publication date

2004-09-30

1995-09-20 Priority claimed from IL11535795A external-priority patent/IL115357A/xx

1996-09-18 Application filed filed Critical

1999-11-02 Publication of JPH11512736A publication Critical patent/JPH11512736A/ja

2004-09-30 Publication of JPH11512736A5 publication Critical patent/JPH11512736A5/ja

2008-06-25 Application granted granted Critical

2008-06-25 Publication of JP4108750B2 publication Critical patent/JP4108750B2/ja

2016-09-18 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

JP51411997A 1995-09-20 1996-09-18 Ｎ−プロパルギル−１−アミノインダンを含有する安定な組成物 Expired - Lifetime JP4108750B2 (ja)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
IL115357		1995-09-20
IL11535795A IL115357A (en)	1995-09-20	1995-09-20	Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols
PCT/IL1996/000115 WO1997012583A2 (en)	1995-09-20	1996-09-18	Stable compositions containing n-propargyl-1-aminoindan

Publications (3)

Publication Number	Publication Date
JPH11512736A JPH11512736A (ja)	1999-11-02
JPH11512736A5 true JPH11512736A5 (2)	2004-09-30
JP4108750B2 JP4108750B2 (ja)	2008-06-25

Family

ID=11068003

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP51411997A Expired - Lifetime JP4108750B2 (ja)	1995-09-20	1996-09-18	Ｎ−プロパルギル−１−アミノインダンを含有する安定な組成物

Country Status (13)

Country	Link
US (1)	US6126968A (2)
EP (1)	EP0858328B1 (2)
JP (1)	JP4108750B2 (2)
AT (1)	ATE362755T1 (2)
AU (1)	AU728524B2 (2)
CA (1)	CA2232310C (2)
DE (1)	DE69637096T2 (2)
DK (1)	DK0858328T3 (2)
ES (1)	ES2287940T3 (2)
HU (1)	HU225859B1 (2)
IL (1)	IL115357A (2)
PT (1)	PT858328E (2)
WO (1)	WO1997012583A2 (2)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5744500A (en)	1990-01-03	1998-04-28	Teva Pharmaceutical Industries, Ltd.	Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
IL118836A (en)	1996-07-11	2001-01-11	Teva Pharma	Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan
JP2003512426A (ja)	1999-10-27	2003-04-02	テバファーマシューティカルインダストリーズリミティド	双極性気分障害における躁病の治療のための１−アミノインダンの使用。
ES2432117T3 (es)	2002-11-15	2013-11-29	Teva Pharmaceutical Industries Limited	Uso de rasagilina con riluzol para tratar la esclerosis lateral amiotrófica
GB2411355B (en)	2004-02-27	2006-02-22	Niche Generics Ltd	Pharmaceutical composition
WO2006014973A2 (en) *	2004-07-26	2006-02-09	Teva Pharmaceutical Industries, Ltd.	Pharmaceutical dosage forms including rasagiline
PT1729735E (pt) *	2004-11-10	2007-08-06	Teva Pharma	Processo de produção de formas de dosagens sólidas comprimidas adequado para utilização com fármacos de baixa solubilidade em água e formas de dosagens sólidas comprimidas assim obtidas
US8367105B2 (en)	2004-11-10	2013-02-05	Teva Pharmaceutical Industries, Ltd.	Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby
ATE521343T1 (de) *	2004-11-24	2011-09-15	Teva Pharma	Im mund zerfallende zusammensetzungen von rasagilin
US20100167983A1 (en) *	2007-10-22	2010-07-01	Teva Pharmaceutical Industries, Ltd.	Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
PL1848415T3 (pl) *	2005-02-17	2013-10-31	Teva Pharma	Terapia kombinowana obejmująca octan glatirameru oraz rasagilinę do leczenia stwardnienia rozsianego
WO2006091657A1 (en) *	2005-02-23	2006-08-31	Teva Pharmaceutical Industries, Ltd.	Rasagiline formulations of improved content uniformity
CA2630037C (en) *	2005-11-17	2015-03-31	Teva Pharmaceutical Industries Ltd.	Methods for isolating propargylated aminoindans
US7572834B1 (en)	2005-12-06	2009-08-11	Teva Pharmaceutical Industries, Ltd.	Rasagiline formulations and processes for their preparation
ES2632638T3 (es)	2005-12-09	2017-09-14	Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.	Ladostigilo de baja dosis para el tratamiento de la deficiencia cognitiva
ES2551481T3 (es)	2006-02-21	2015-11-19	Teva Pharmaceutical Industries, Ltd.	Uso de rasagilina para el tratamiento de atrofia multisistémica
TW200744576A (en)	2006-02-24	2007-12-16	Teva Pharma	Propargylated aminoindans, processes for preparation, and uses thereof
JP5769923B2 (ja) *	2006-04-03	2015-08-26	テバファーマシューティカルインダストリーズリミティド	レストレスレッグス症候群の治療のためのラサギリンの使用
DE202006020710U1 (de)	2006-05-09	2009-12-31	Teva Pharmaceutical Industries Ltd.	Zusammensetzungen mit Rosiglitazonmaleat
EP1892233A1 (de) *	2006-08-18	2008-02-27	Ratiopharm GmbH	Neue Salze des Wirkstoffs Rasagilin
CN101557706B (zh) *	2006-12-14	2013-08-07	泰华制药工业有限公司	雷沙吉兰碱结晶固体
CN101600346B (zh) *	2006-12-14	2013-08-21	泰华制药工业有限公司	雷沙吉兰的单宁酸盐
EP1987816A1 (de) *	2007-04-30	2008-11-05	Ratiopharm GmbH	Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
CA2698695A1 (en) *	2007-09-05	2009-03-12	Teva Pharmaceutical Industries Ltd.	Method of treating glaucoma using rasagiline
US8188149B2 (en) *	2007-09-17	2012-05-29	Teva Pharmaceutical Industries, Ltd.	Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss
EP2234478A4 (en) *	2008-01-11	2013-01-23	Teva Pharma	RASAGILINE FORMULATIONS, THEIR PREPARATION AND USE
US20090247537A1 (en) *	2008-03-25	2009-10-01	William Dale Overfield	Methods for preventing or treating bruxism using dopaminergic agents
US20110117200A1 (en) *	2008-03-31	2011-05-19	Actavis Group Ptc Ehf	Rasagiline mesylate particles and process for the preparation thereof
MX2010013766A (es) *	2008-06-13	2011-03-15	Teva Pharmaceutical Ind Ltd Star	Rasagilina para modificacion de enfermedad de parkinson.
BRPI0909997A2 (pt)	2008-06-19	2015-10-27	Teva Pharma	r(+)-n-propargil-1-aminoindano cristalino, composição farmacêutica, processo de secagem de r(+)-n-propargil-1-aminoindano sólido, processo de preparação de uma composição farmacêutica, processo de produção de um lote validado de um produto de farmaco que contém r(+)-n-propargil-1-aminoindano cristalino e pelo menos um veículo farmaceuticamente aceitável para distribuição e processo de prudução de r(+)-n-propargil-1-aminoindano cristalino
US8334409B2 (en) *	2008-06-19	2012-12-18	Teva Pharmaceutical Industries, Ltd.	Process for purifying rasagiline base
US20100189791A1 (en) *	2009-01-23	2010-07-29	Teva Pharmaceutical Industries, Ltd.	Delayed release rasagiline malate formulation
EP2218444A3 (en)	2009-01-23	2010-08-25	Teva Pharmaceutical Industries, Ltd.	Delayed release rasagiline formulation
KR20110130410A (ko)	2009-03-05	2011-12-05	산도즈 아게	라사길린 메실레이트를 함유하는 제약 조성물
SI2451771T1 (sl)	2009-07-09	2014-10-30	Ratiopharm Gmbh	Soli rasagilina in njihovi farmacevtski pripravki
CN102048717B (zh) *	2009-10-29	2014-02-19	重庆医药工业研究院有限责任公司	一种稳定的雷沙吉兰组合物
EP2515891A4 (en)	2009-12-22	2013-06-05	Teva Pharma	3-keto-N-propargyl-1-aminoindan
MX2012012069A (es)	2010-04-30	2012-11-22	Teikoku Pharma Usa Inc	Composiciones transdermicas de propinilaminoindan.
EP2389927A1 (en)	2010-05-30	2011-11-30	Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi	Pharmaceutical formulations of rasagiline
AU2011282720B2 (en)	2010-07-27	2016-12-22	Teva Pharmaceutical Industries Ltd.	Use of rasagiline for the treatment of olfactory dysfunction
JP2013537530A (ja)	2010-07-27	2013-10-03	テバファーマシューティカルインダストリーズリミティド	ラサギリンシトレートの分散物
KR101853082B1 (ko)	2011-03-24	2018-04-27	테이코쿠 팔마 유에스에이, 인코포레이티드	활성제층 및 활성제 변환층을 포함하는 경피 조성물
HK1200315A1 (en) *	2011-10-10	2015-08-07	Teva Pharmaceutical Industries Ltd.	R(+)-n-formyl-propargyl-aminoindan
JP2014534197A (ja)	2011-10-10	2014-12-18	テバファーマシューティカルインダストリーズリミティド	Ｒ（＋）−ｎ−メチル−プロパルギルアミノインダン
AU2012323346A1 (en) *	2011-10-10	2014-05-15	Teva Pharmaceutical Industries Ltd	Rasagiline citramide
JP5913614B2 (ja)	2011-11-09	2016-04-27	テイコクファーマユーエスエーインコーポレーテッド	皮膚新生物の処置方法
DE102012000786A1 (de)	2012-01-18	2013-07-18	Stada Arzneimittel Ag	Verfahren zur Herstellung einer festen pharmazeutischen Zusammensetzung, enthaltend den Wirkstoff Rasagilin
EA201491734A1 (ru)	2012-03-21	2015-01-30	Синтон Бв	Стабилизированные фармацевтические композиции, содержащие соли разагилина
WO2013175493A1 (en)	2012-04-09	2013-11-28	Cadila Healthcare Limited	Stable oral pharmaceutical compositions
JP2015529196A (ja)	2012-08-17	2015-10-05	テバファーマシューティカルインダストリーズリミティド	ラサギリンの非経口製剤
JP6050896B2 (ja)	2012-11-02	2016-12-21	テイコクファーマユーエスエーインコーポレーテッド	プロピニルアミノインダン経皮組成物
ES2502140T1 (es) *	2013-02-06	2014-10-02	Galenicum Health S.L.	Comprimidos de liberación inmediata de rasagilina hemitartrato
EP2796130A3 (en) *	2013-02-06	2015-02-25	Galenicum Health S.L.	Immediate release tablets of rasagiline hemitartrate
CN115400090A (zh) *	2022-10-09	2022-11-29	北京新领先医药科技发展有限公司	一种雷沙吉兰的口崩片组合物及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1187017A (en) *	1966-07-16	1970-04-08	Aspro Nicholas Ltd	Substituted 1-Amino Indanes and Tetrahydronaphthalens
GB8909793D0 (en) *	1989-04-28	1989-06-14	Beecham Group Plc	Pharmaceutical formulation
IL92952A (en) *	1990-01-03	1994-06-24	Teva Pharma	R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
CA2039742A1 (en) *	1990-04-23	1991-10-24	Andrew B. Dennis	Tablet composition and method for problem pharmaceutical materials
IL99759A (en) *	1991-10-16	1997-06-10	Teva Pharma	Mono-fluorinated derivatives of n-propargyl-1-aminoindan, their preparation and pharmaceutical compositions containing them
IL111240A (en) *	1993-10-18	2001-10-31	Teva Pharma	Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them
IL112779A (en) *	1994-03-01	1999-11-30	Gergely Gerhard	Granular product or tablet containing an efferescent system and an active pharmaceutical substance and its preparation
BR9607057A (pt) *	1995-03-02	1998-06-09	Scherer Ltd R P	Composições farmacêuticas compreendendo inibidores monoamina oxidase b

1995
- 1995-09-20 IL IL11535795A patent/IL115357A/xx not_active IP Right Cessation
1996
- 1996-09-18 PT PT96930344T patent/PT858328E/pt unknown
- 1996-09-18 DE DE69637096T patent/DE69637096T2/de not_active Expired - Lifetime
- 1996-09-18 JP JP51411997A patent/JP4108750B2/ja not_active Expired - Lifetime
- 1996-09-18 DK DK96930344T patent/DK0858328T3/da active
- 1996-09-18 HU HU9802999A patent/HU225859B1/hu unknown
- 1996-09-18 ES ES96930344T patent/ES2287940T3/es not_active Expired - Lifetime
- 1996-09-18 US US09/043,475 patent/US6126968A/en not_active Expired - Lifetime
- 1996-09-18 AT AT96930344T patent/ATE362755T1/de active
- 1996-09-18 AU AU69427/96A patent/AU728524B2/en not_active Expired
- 1996-09-18 CA CA002232310A patent/CA2232310C/en not_active Expired - Lifetime
- 1996-09-18 WO PCT/IL1996/000115 patent/WO1997012583A2/en not_active Ceased
- 1996-09-18 EP EP96930344A patent/EP0858328B1/en not_active Expired - Lifetime

Publication	Publication Date	Title
JP2000500228A5 (2)	2004-09-09
JPH11510278A5 (2)	2004-08-26
JP2000500445A5 (2)	2004-10-14
JP2000500440A5 (2)	2004-10-21
JP2000504925A5 (2)	2004-10-14
JP2001517960A5 (2)	2004-09-09
JPH11508813A5 (2)	2004-07-22
JP2000500327A5 (2)	2005-10-06
JPH11513262A5 (2)	2004-09-16
JP2000500145A5 (2)	2004-10-14
JP2000500155A5 (2)	2004-10-21
JPH11506001A5 (2)	2004-07-08
JPH11512885A5 (2)	2004-09-30
JP2000500406A5 (2)	2004-10-14
JP2000500361A5 (2)	2004-10-14
JPH11512736A5 (2)	2004-09-30
JP2000500322A5 (2)	2004-09-30
JP2000500258A5 (2)	2004-08-12
JP2000500342A5 (2)	2004-10-21
JP2000500192A5 (2)	2004-07-15
JP2000500112A5 (2)	2004-10-14
JP2000500226A5 (2)	2004-08-12
JP2000500407A5 (2)	2004-10-21
JP2000500397A5 (2)	2004-10-21
JP2000500166A5 (2)	2004-09-24